Basic Study
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jul 15, 2021; 13(7): 693-705
Published online Jul 15, 2021. doi: 10.4251/wjgo.v13.i7.693
Cryptotanshinone inhibits cytotoxin-associated gene A-associated development of gastric cancer and mucosal erosions
Zhang-Ming Chen, Jie Hu, Yuan-Min Xu, Wei He, Lei Meng, Ting Huang, Song-Cheng Ying, Zhe Jiang, A-Man Xu
Zhang-Ming Chen, Jie Hu, A-Man Xu, Department of General Surgery, Fourth Affiliated Hospital of Anhui Medical University, Hefei 230001, Anhui Province, China
Yuan-Min Xu, Lei Meng, Zhe Jiang, Department of General Surgery, First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui Province, China
Wei He, Department of Surgery, East District of First Affiliated Hospital of Anhui Medical University (Feidong People's Hospital), Hefei 230001, Anhui Province, China
Ting Huang, Song-Cheng Ying, Department of Immunology, School of Basic Medical Sciences, Anhui Medical University, Hefei 230032, Anhui Province, China
Author contributions: Chen ZM, Hu J, and Xu YM contributed equally to this work; Xu AM, Jiang Z, and Ying SC designed the study; Chen ZM, Hu J, and Xu YM conducted the experiments and analyzed the data; He W, Meng L, and Huang T provided materials and participated in the data analyses; Chen ZM and Jiang Z wrote the manuscript; Ying SC and Xu AM participated in the revision of the manuscript.
Supported by National Natural Science Foundation of China, No. 81572350
Institutional review board statement: The study was reviewed and approved by the Institutional Review Board of First Affiliated Hospital of Anhui Medical University.
Institutional animal care and use committee statement: The protocol for the animal experiments was approved by the Laboratory Animal Ethics Committee of Anhui Medical University.
Informed consent statement: All patients signed the informed consent.
Conflict-of-interest statement: The authors declare that they have no competing interests.
Data sharing statement: No additional data are available.
ARRIVE guidelines statement: The authors have read the ARRIVE Guidelines, and the manuscript was prepared and revised according to the ARRIVE Guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: A-Man Xu, MD, PhD, Professor, Department of General Surgery, Fourth Affiliated Hospital of Anhui Medical University, No. 100 Huaihai Avenue, Hefei 230001, Anhui Province, China. xamhwx@163.com
Received: March 4, 2021
Peer-review started: March 4, 2021
First decision: April 17, 2021
Revised: April 19, 2021
Accepted: June 1, 2021
Article in press: June 1, 2021
Published online: July 15, 2021
Processing time: 127 Days and 19 Hours
Core Tip

Core Tip: Cryptotanshinone inhibited cytotoxin-associated gene A (CagA)-induced proliferation and the epithelial-mesenchymal transition of gastric cancer cells in vitro, and Helicobacter pylori (H. pylori)CagA-positive strains caused mucosal erosions of stomach in vivo by decreasing the expression of SHP2 protein, which could be an effective drug in treating H. pylori infection.